Medgenics (LON:MEDG) , the Israel based biotechnology group, has been given the go-ahead by the country’s Ministry of Health to proceed with higher dose groups in the phase I-II clinical trial of its novel sustained anaemia treatment, EPODURE. The company is funding the new study with cash raised in a £0.7 million fundraising that was completed in March.

Medgenics has already reported sustained anaemia treatment of unprecedented duration from a single treatment in most patients in the low dose group in its study and now hopes to prove the efficacy of EPODURE in the higher dose study.

The testing will be carried out at a new site, the Tel Aviv Sourasky Medical Centre, which is one of the largest teaching hospitals in Israel. Patient recruitment is set to begin shortly for the new centre, with the first patients expected to receive their Biopumps within a few weeks of enrolment.

Dr Andrew Pearlman, the chief executive of Medgenics, said: “This important step has been made possible by the encouraging results achieved to date, together with the first closing of our current round of fundraising, and we look forward to moving ahead on this and other steps in our program as additional funds are raised in the coming months. Given the very encouraging results at low dose levels, we are looking much forward to seeing the results from the higher doses in this trial.”

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here